低流量低梯度主动脉瓣狭窄患者TAVR预后:TOPAS-TAVI注册研究
该多中心注册研究纳入287例经导管主动脉瓣置换(TAVR)的低流量低梯度主动脉瓣狭窄(LFLG-AS)患者,其中234例术前接受多巴酚丁胺负荷超声(DSE)。TAVR围术期结局良好,但2年死亡率达32.3%,慢性阻塞性肺疾病、低血红蛋白及术后中重度主动脉瓣反流与不良结局相关;LVEF在1年随访时平均提高8.3%,而DSE未能预测临床结局或LVEF变化。
要点
- LFLG-AS患者TAVR围术期结局良好,但2年死亡率达32.3%。
- 慢性阻塞性肺疾病、低血红蛋白与全因死亡相关。
- LVEF在TAVR后1年平均提高8.3%,DSE无预测价值。
核心结论
- TAVR在LFLG-AS患者中围术期结局良好,但约三分之一患者2年内死亡。
- 肺疾病、贫血和残余瓣周漏与较差结局相关。
- TAVR后LVEF改善,但DSE未能预测临床结局或LVEF变化。
研究设计与样本
- 多中心注册研究,纳入287例接受TAVR的LFLG-AS患者。
- 234例术前接受DSE,收缩储备定义为每搏输出量增加≥20%。
- 术后住院期间及1年重复经胸超声心动图,临床随访至2年。
主要发现
- 中位STS评分为7.7%(四分位距5.3%–12.0%),平均LVEF为30.1±9.7%,平均跨瓣压差为25.4±6.6 mmHg。
- 45%的患者在DSE中检出收缩储备。
- 30天、1年和2年死亡率分别为3.8%、20.1%和32.3%。
- 多变量分析显示慢性阻塞性肺疾病(p=0.022)和较低血红蛋白(p<0.001)与全因死亡相关。
- 较低血红蛋白(p=0.004)和TAVR后中重度主动脉瓣反流(p=0.018)是全因死亡与心衰再住院复合终点的预测因素。
临床怎么用
- LFLG-AS患者行TAVR需综合评估,关注慢性阻塞性肺疾病、贫血及术后瓣周漏。
- DSE结果不应作为LFLG-AS患者TAVR决策的唯一依据。
- TAVR后LVEF可改善,基线LVEF较低者改善更明显。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data exist on patients with low-flow, low-gradient aortic stenosis (LFLG-AS) undergoing transcatheter aortic valve replacement (TAVR). Also, very scarce data exist on the usefulness of dobutamine stress echocardiography (DSE) before TAVR in these patients. OBJECTIVES: The authors sought to evaluate clinical outcomes and changes in left ventricular ejection fraction (LVEF) following TAVR in patients with classical LFLG-AS. METHODS: This multicenter registry included 287 patients with LFLG-AS undergoing TAVR. DSE was performed before TAVR in 234 patients and the presence of contractile reserve was defined as an increase of ≥20% in stroke volume. Transthoracic echocardiography was repeated at hospital discharge and at 1-year follow-up. Clinical follow-up was obtained at 1 and 12 months, and yearly thereafter. RESULTS: The median Society of Thoracic Surgeons score of the study population was 7.7% (interquartile range 5.3% to 12.0%), and the mean LVEF and transvalvular gradient were 30.1 ± 9.7% and 25.4 ± 6.6 mm Hg, respectively. The presence of contractile reserve was observed in 45% of patients at DSE. Mortality rates were 3.8%, 20.1%, and 32.3% at 30 days, 1 year, and 2 years, respectively. On multivariable analysis, chronic obstructive pulmonary disease (p = 0.022) and lower hemoglobin values (p < 0.001) were associated with all-cause mortality. Lower hemoglobin values (p = 0.004) and moderate-to-severe aortic regurgitation post-TAVR (p = 0.018) were predictors of the composite of mortality and rehospitalization due to heart failure. LVEF increased by 8.3% (95% confidence interval: 6% to 11%) at 1-year follow-up, and the lack of prior coronary artery bypass graft (p = 0.004), a lower LVEF at baseline (p < 0.001), and a lower stroke volume index at baseline (p = 0.019) were associated with greater increase in LVEF. The absence of contractile reserve at baseline DSE was not associated with any negative effect on clinical outcomes or LVEF changes at follow-up. CONCLUSIONS: TAVR was associated with good periprocedural outcomes in patients with LFLG-AS. However, approximately one-third of LFLG-AS TAVR recipients died at 2-year follow-up, with pulmonary disease, anemia, and residual paravalvular leaks associated with poorer outcomes. LVEF improved following TAVR, but DSE failed to predict clinical outcomes or LVEF changes over time. (Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis [TOPAS Study]; NCT01835028).
引用
- Ribeiro HB, Lerakis S, Gilard M, et al. Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry. J Am Coll Cardiol. 2018. PMID: 29566812. doi:10.1016/j.jacc.2018.01.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。